RANK ligand and osteoprotegerin: Paracrine regulators of bone metabolism and vascular function

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 22, Issue 4, 2002, Pages 549-553

  Schoppet, Michael ^a   Preissner, Klaus T ^a   Hofbauer, Lorenz C ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Arterial calcification; Dendritic cells; Osteoporosis; Osteoprotegerin; RANK ligand

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ARTERY CALCIFICATION; BONE METABOLISM; CELL SURVIVAL; DENDRITIC CELL; HORMONAL REGULATION; HUMAN; NONHUMAN; OSTEOPOROSIS; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANIMALS; ARTERIES; BONE AND BONES; BONE REMODELING; BONE RESORPTION; CALCINOSIS; CARRIER PROTEINS; GLYCOPROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; OSTEOPETROSIS; OSTEOPOROSIS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; VASCULAR DISEASES;

EID: 0036120427     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000012303.37971.DA     Document Type: Short Survey

References (74)

1. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
2. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis
3. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro
4. TR1, a new member of the tumor necrosis factor receptor family, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption
5. OPG/FDCR-I, a TNT receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40
6. Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption: The American Society for Bone and Mineral Research President's Committee on Nomenclature
7. Structure of the mouse osteoclastogenesis inhibitory factor (OCIF) gene and its expression in embryogenesis
8. Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor
9. An integrated physical map of 8q22-q24: Use in positional cloning and deletion analysis of Langer-Giedion syndrome
10. The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function
11. Characterization of structural domains of human osteoclastogenesis inhibitory factor
12. Modulation of life and death by the TNF receptor superfamily
13. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor
14. A novel protein domain required for apoptosis: Mutational analysis of human Fas antigen
15. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95
16. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL
17. Stimulus-dependent synergism of the antiapoptotic tumor necrosis factor receptor-associated factor 2 (TRAF2) and nuclear factor-κB pathways
18. Vascular endothelial growth factor is a secreted angiogenic mitogen
19. Threedimensional structure of human basic fibroblast growth factor
20. Three-dimensional structure of human basic fibroblast growth factor, a structural homolog of interleukin 1β
21. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and nonhematopoietic cells
22. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells
23. Osteoprotegerin mRNA is increased by interleukin-1 a in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells
24. Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells
25. Transforming growth factor-β stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells
26. Transcriptional mechanisms of bone morphogenetic protein-induced osteoprotegerin gene expression
27. Receptor activator of NF-κB and osteoprotegerin expression by human microvascular cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis
28. 17β-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-α
29. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells
30. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: Downregulation by glucocorticoids
31. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid- induced osteoporosis
32. Effects of immunosuppressants on receptor activator of NF-κB ligand and osteoprotegerin production by human osteoblastic and coronary smooth muscle cells
33. In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene
34. 2 in human bone marrow stroma cells
35. Basic fibroblast growth factor induces osteoclast formation by reciprocally regulating the production of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in mouse osteoblastic cells
36. Force-induced osteoclast apoptosis in vivo is accompanied by elevation in transforming growth factor-β and osteoprotegerin expression
37. Age-related decline inosteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges
38. Osteoprotegerin ligand: A regulator of immune responses and bone physiology
39. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
40. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
41. Evidence for a role of a tumor necrosis factor-α (TNF-α)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival
42. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
43. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis
44. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
45. Expression of functional RANK on mature rat and human osteoclasts
46. TRANCE-RANK a new signal pathway involved in lymphocyte development and T cell activation
47. RANKing the importance of measles virus in Paget's disease
48. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesisinhibitory factor and is identical to TRANCE/RANKL
49. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
50. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin
51. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
52. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families
53. Bone resorption by osteoclasts
54. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function
55. Trance, a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor
56. Trance, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells
57. Trance, a TNF family member, enhances the longevity and adjuvant properties of dendritic cells in vivo
58. Trance, a TNF family member critical for CD40 ligand-independent T helper cell activation
59. RANK is essential for osteoclast and lymph node development
60. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function
61. To die or not to die: The quest of the TRAIL receptors
62. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
63. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis
64. Spiral CT quantification of aorto-renal calcification and its use in the detection of atheromatous renal artery stenosis: A study in 42 patients
65. 3-induced, NF-κB -dependent survival factor for endothelial cells
66. Progression of aortic calcification is associated with metacarpal bone loss during menopause: A population-based longitudinal study
67. Rate of bone loss is associated with mortality in older women: A prospective study
68. Calcification of the aorta and osteoporosis. A roentgenographic study
69. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women
70. Immunological characterization of circulating osteoprotegerin/osteoclasto-genesis inhibitory factor: Increased serum concentrations in postmenopausal women with osteoporosis
71. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D
72. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption
73. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques
74. The effect of a single dose of osteoprotegerin in postmenopausal women